Department of Pharmaceutical Chemistry, University of Vienna, 1090 Vienna, Austria.
Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090 Vienna, Austria.
Phytomedicine. 2020 Dec;79:153357. doi: 10.1016/j.phymed.2020.153357. Epub 2020 Sep 25.
Actaea racemosa L., also known as black cohosh, is a popular herb commonly used for the treatment of menopausal symptoms. Because of its purported estrogenic activity, black cohosh root extract (BCE) may trigger breast cancer growth.
STUDY DESIGN/METHODS: The potential effects of standardized BCE and its main constituent actein on cellular growth rates and steroid hormone metabolism were investigated in estrogen receptor alpha positive (ERα+) MCF-7 and -negative (ERα-) MDA-MB-231 human breast cancer cells. Cell numbers were determined following incubation of both cell lines with the steroid hormone precursors dehydroepiandrosterone (DHEA) and estrone (E1) for 48 h, in the presence and absence of BCE or actein. Using a validated liquid chromatography-high resolution mass spectrometry assay, cell culture supernatants were simultaneously analyzed for the ten main steroids of the estrogen pathway.
Inhibition of MCF-7 and MDA-MB-231 cell growth (up to 36.9%) was observed following treatment with BCE (1-25 µg/ml) or actein (1-50 µM). Incubation of MCF-7, but not of MDA-MB-231 cells, with DHEA and BCE caused a 20.9% reduction in DHEA-3-O-sulfate (DHEA-S) formation, leading to a concomitant increase in the androgens 4-androstene-3,17-dione (AD) and testosterone (T). Actein was shown to exert an even stronger inhibitory effect on DHEA-S formation in MCF-7 cells (up to 89.6%) and consequently resulted in 12- to 15-fold higher androgen levels compared with BCE. The formation of 17β-estradiol (E2) and its glucuronidated and sulfated metabolites was not affected by BCE or actein after incubation with the estrogen precursor estrone (E1) in either cell line.
The results of the present study demonstrated that actein and BCE do not promote breast cancer cell growth or influence estrogen levels. However, androgen formation was strongly stimulated by BCE and actein, which may contribute to their ameliorating effects on menopausal symptoms in women. Future studies monitoring the levels of AD and T upon BCE supplementation of patients are warranted to verify an association between BCE and endogenous androgen metabolism.
升麻,又称黑升麻,是一种常用的草药,常用于治疗更年期症状。由于其被认为具有雌激素活性,黑升麻根提取物(BCE)可能会引发乳腺癌生长。
研究设计/方法:研究了标准化 BCE 及其主要成分升麻苷对雌激素受体 alpha 阳性(ERα+)MCF-7 和阴性(ERα-)MDA-MB-231 人乳腺癌细胞的细胞生长率和类固醇激素代谢的潜在影响。在存在和不存在 BCE 或升麻苷的情况下,用类固醇激素前体脱氢表雄酮(DHEA)和雌酮(E1)孵育两种细胞系 48 小时后,确定细胞数量。使用经过验证的液相色谱-高分辨率质谱分析,同时分析细胞培养上清液中雌激素途径的十种主要类固醇。
用 BCE(1-25μg/ml)或升麻苷(1-50μM)处理后,观察到 MCF-7 和 MDA-MB-231 细胞的生长抑制(高达 36.9%)。孵育 MCF-7 细胞,但不孵育 MDA-MB-231 细胞,用 DHEA 和 BCE 处理会导致 DHEA-3-O-硫酸盐(DHEA-S)形成减少 20.9%,从而导致雄激素 4-雄烯二酮(AD)和睾酮(T)增加 12-15 倍。升麻苷对 MCF-7 细胞中 DHEA-S 形成的抑制作用更强(高达 89.6%),与 BCE 相比,导致雄激素水平升高 12-15 倍。用雌激素前体雌酮(E1)孵育后,BCE 或升麻苷均不影响 E2 及其葡糖苷酸和硫酸盐代谢物的形成。
本研究结果表明,升麻苷和 BCE 既不会促进乳腺癌细胞生长,也不会影响雌激素水平。然而,BCE 和升麻苷强烈刺激雄激素的形成,这可能有助于它们改善女性更年期症状。未来的研究需要监测接受 BCE 补充的患者的 AD 和 T 水平,以验证 BCE 与内源性雄激素代谢之间的关联。